A clinical genetics company, GeneDx runs DNA testing laboratories that use whole-genome and whole-exome sequencing to help doctors diagnose rare and inherited disorders, especially in children and critical-care patients. Two National Institutes of Health scientists founded the original GeneDx in 2000 in a small Maryland lab, naming it for "gene" plus "Dx," the medical shorthand for diagnosis. The firm merged with the genomics company Sema4 in 2022, and the combined business now carries the GeneDx name.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -104.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.